QUIDEL CORP /DE/
DelistedCIK 353569fmd_0RX9BP7DCBSY0FQAPXV51C7KYRManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2022, 49 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 156 | 177 | 184 | 196 | 192 | 278 | 522 | 535 | 1,662 | 1,699 |
| Cost of revenue | 61 | 67 | 74 | 78 | 80 | 122 | 207 | 214 | 313 | 428 |
| Gross profit | 94 | 110 | 110 | 118 | 112 | 156 | 316 | 321 | 1,349 | 1,271 |
| Research and development | 28 | 34 | 38 | 36 | 39 | 34 | 52 | 53 | 84 | 96 |
| Selling, general and administrative | 50 | 61 | 69 | 77 | 77 | 96 | 154 | 164 | 201 | 260 |
| Operating income | 10 | 5 | (9) | 3 | (4) | 10 | 96 | 93 | 1,060 | 906 |
| Interest expense | 1 | 1 | 1 | 11 | 11 | 11 | 6 | 2 | 1 | – |
| Interest and investment income | 0 | 0 | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (1) | (1) | – | – | (12) | (18) | (33) | (16) | (20) | (6) |
| Income before taxes | 8 | 3 | (11) | (9) | (16) | (8) | 63 | 77 | 1,040 | 900 |
| Income tax expense | 3 | (4) | (4) | (3) | (2) | 0 | (11) | 4 | 230 | 196 |
| Net income from continuing operations | 5 | 7 | (7) | (6) | (14) | (8) | 74 | 73 | 810 | 704 |
| Net income | 5 | 7 | (7) | (6) | (14) | (8) | 74 | 73 | 810 | 704 |
| Net income to common shareholders | 5 | 7 | – | – | (14) | (8) | 79 | 75 | 811 | 704 |